L. E. B. Johansson

6.8k total citations · 2 hit papers
160 papers, 3.9k citations indexed

About

L. E. B. Johansson is a scholar working on Astronomy and Astrophysics, Spectroscopy and Epidemiology. According to data from OpenAlex, L. E. B. Johansson has authored 160 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Astronomy and Astrophysics, 38 papers in Spectroscopy and 31 papers in Epidemiology. Recurrent topics in L. E. B. Johansson's work include Astrophysics and Star Formation Studies (58 papers), Stellar, planetary, and galactic studies (27 papers) and Liver Disease Diagnosis and Treatment (21 papers). L. E. B. Johansson is often cited by papers focused on Astrophysics and Star Formation Studies (58 papers), Stellar, planetary, and galactic studies (27 papers) and Liver Disease Diagnosis and Treatment (21 papers). L. E. B. Johansson collaborates with scholars based in Sweden, United States and Russia. L. E. B. Johansson's co-authors include Håkan Åhlström, Joel Kullberg, Jan Oscarsson, Jan W. Eriksson, Olle Korsgren, Lars Lind, Olof Eriksson, Per‐Anders Jansson, Ulf Risérus and R. S. Booth and has published in prestigious journals such as Nature Communications, PLoS ONE and The Astrophysical Journal.

In The Last Decade

L. E. B. Johansson

150 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

2018 287 citations L. E. B. Johansson, Jan Oscarsson et al. profile →
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

2021 146 citations L. E. B. Johansson, Rohit Loomba et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. E. B. Johansson Sweden	33	1.1k	1.1k	827	745	668	160	3.9k
H. Schatz Germany	39	712 0.6×	173 0.2×	588 0.7×	2.2k 3.0×	592 0.9×	265	6.2k
Yukio Ikeda Japan	43	866 0.8×	649 0.6×	1.1k 1.3×	965 1.3×	1.8k 2.6×	242	6.5k
Naoki Iwamoto Japan	34	347 0.3×	440 0.4×	365 0.4×	589 0.8×	1.2k 1.8×	233	4.9k
D. Ramsden United Kingdom	40	706 0.6×	531 0.5×	170 0.2×	142 0.2×	1.7k 2.6×	252	5.3k
P. Schwändt Germany	39	1.1k 1.0×	324 0.3×	1.2k 1.4×	47 0.1×	569 0.9×	388	6.0k
Satoko Nakamura Japan	33	696 0.6×	229 0.2×	703 0.9×	613 0.8×	459 0.7×	184	4.3k
Henning B. Nielsen Denmark	43	188 0.2×	331 0.3×	820 1.0×	203 0.3×	641 1.0×	153	6.7k
Riccardo Ricci Italy	34	465 0.4×	1.4k 1.2×	1.6k 1.9×	183 0.2×	1.1k 1.6×	162	5.2k
James W. Ryan United States	39	361 0.3×	152 0.1×	486 0.6×	187 0.3×	2.1k 3.1×	206	5.4k
Michio Hashimoto Japan	43	352 0.3×	156 0.1×	783 0.9×	233 0.3×	1.5k 2.3×	246	6.4k

Countries citing papers authored by L. E. B. Johansson

Since Specialization

Citations

This map shows the geographic impact of L. E. B. Johansson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. E. B. Johansson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. E. B. Johansson more than expected).

Fields of papers citing papers by L. E. B. Johansson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. E. B. Johansson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. E. B. Johansson. The network helps show where L. E. B. Johansson may publish in the future.

Co-authorship network of co-authors of L. E. B. Johansson

This figure shows the co-authorship network connecting the top 25 collaborators of L. E. B. Johansson. A scholar is included among the top collaborators of L. E. B. Johansson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. E. B. Johansson. L. E. B. Johansson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laitinen, Iina, Helena Litorp, Folke Sjöberg, et al.. (2025). Tissue-specific and whole-body insulin sensitivity by integrated imaging and hyperinsulinemic euglycemic clamp: A repeatability study in people with T2DM and overweight/obesity. EJNMMI Research. 15(1). 105–105.

Goodman, James, Martin Schain, Giovanni Di Stefano, et al.. (2025). Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes. Scientific Reports. 15(1). 21404–21404.

Parker, Victoria, Darren Robertson, Bas Havekes, et al.. (2023). Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes. Nature Metabolism. 5(12). 2086–2093. 35 indexed citations

Loomba, Rohit, Eric Lawitz, Juan P. Frías, et al.. (2022). Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. The Lancet. Gastroenterology & hepatology. 8(2). 120–132. 72 indexed citations

Latva‐Rasku, Aino, Miikka‐Juhani Honka, Joel Kullberg, et al.. (2019). The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients. Diabetes Care. 42(5). 931–937. 183 indexed citations

Selvaraju, Ram Kumar, Irina Velikyan, Daniel Espes, et al.. (2012). Pancreatic uptake of [68Ga]DO3A-Exendin4 is mediated by the GLP-1 receptor. European Journal of Nuclear Medicine and Molecular Imaging. 39.

Kalenskiĭ, S. V., L. E. B. Johansson, P. Bergman, et al.. (2010). Search for Class I methanol masers in low-mass star formation regions. Monthly Notices of the Royal Astronomical Society. 32 indexed citations

Pirogov, L. E., И. И. Зинченко, L. E. B. Johansson, & Ji Yang. (2009). A search for small-scale clumpiness in Orion and W3 high-mass star-forming regions. 27(3). 475–478. 1 indexed citations

Sutin, Lori, Sören Andersson, Víctor M. Castro, et al.. (2007). Oxazolones as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorganic & Medicinal Chemistry Letters. 17(17). 4837–4840. 29 indexed citations

10.

Nyman, L. Å., M. S. Lerner, M. Nielbock, et al.. (2001). SIMBA Explores the Southern Sky. Msngr. 106. 40–44. 2 indexed citations

11.

Kalenskiĭ, S. V., et al.. (2000). Probing the properties of methyl cyanide sources. Chalmers Publication Library (Chalmers University of Technology). 9 indexed citations

12.

Johansson, L. E. B., et al.. (1999). Molecular abundance variations in the Magellanic Clouds. Chalmers Publication Library (Chalmers University of Technology). 13 indexed citations

13.

Booth, R. S., et al.. (1996). A CO survey of galaxies with the SEST and the 20-m Onsala telescope.. 115. 439–468.

14.

Aalto, S., et al.. (1995). Molecular gas in starburst galaxies: Line intensities and physical conditions. NASA STI/Recon Technical Report N. 300. 30569. 6 indexed citations

15.

Lindqvist, M., Å. Sandqvist, A. Winnberg, L. E. B. Johansson, & L. Å. Nyman. (1995). C^18^O and HNCO in the Galactic Centre. I. Observational data.. Astronomy & Astrophysics Supplement Series. 113. 257. 7 indexed citations

16.

Bengtsson, Stefan, et al.. (1990). Potential antipsychotic agents. 5. Synthesis and antidopaminergic properties of substituted 5,6-dimethoxysalicylamides and related compounds. Journal of Medicinal Chemistry. 33(4). 1155–1163. 26 indexed citations

17.

Olofsson, H., et al.. (1989). Molecular emission lines from the envelopes of evolved stars.. A&A. 210. 78–92. 1 indexed citations

18.

Booth, R. S., R. M. González Delgado, Magnus Hagström, et al.. (1988). The Swedish-ESO Submillimeter Telescope (SEST). NASA STI/Recon Technical Report N. 216. 27605–324. 9 indexed citations

19.

Irvine, William M., Per Friberg, Å. Hjalmarson, et al.. (1984). Confirmation of the Existence of Two New Interstellar Molecules: C 3 H and C 3 O. Bulletin of the American Astronomical Society. 16. 877. 3 indexed citations

20.

Johansson, L. E. B., et al.. (1979). Absolute configuration of potentially neuroleptic rigid spiro amines. A study on the topography of the neuroleptic receptor.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 16(4). 239–46. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact